

Table S12. Predictors of remission at 6 and 12 months of treatment with abatacept in rheumatoid arthritis patients (bivariate analysis)

	6 MONTHS							12 MONTHS					
Clinical variable	Remission						Clinical variable	Remission					
	N	No Remission	Remission	p	OR	95% CI		N	No Remission	Remission	p	OR	95% CI
Sex							Sex						
Women	89	78 (87.6)	11 (12.4)	0.169	–	–	Women	75	56 (74.7)	19 (25.3)	0.471	–	–
Men	31	24 (77.4)	7 (22.6)				Men	30	20 (66.7)	10 (33.3)			
Smoking							Smoking						
Smoker	18	13 (72.2)	5 (27.8)	0.211	–	–	Smoker	16	11 (68.8)	5 (31.2)	0.816	–	–
Ex-smoker	14	13 (92.9)	1 (7.1)				Ex-smoker	12	8 (66.7)	4 (33.3)			
Non-smoker	88	76 (86.4)	12 (13.6)				Non-smoker	77	57 (74)	20 (26)			
Age at Dx	120	45.56 ± 13.84	42.83 ± 13.53	0.439	–	–	Age at Dx	105	45.76 ± 13.64	44.44 ± 15.29	0.670	–	–
Years with RA	120	16 (10–21)	13.5 (6.75–21.25)	0.142	–	–	Years with RA	105	16.5 (12–22.25)	10 (7–18)	0.655	–	–
ABA start age	120	57.52 ± 13.13	51.56 ± 12.86	0.073	–	–	ABA start age	105	58.46 ± 13.03	53.17 ± 13.77	0.070	–	–
ABA duration	120	24 (14–45.25)	25.5 (15–39.50)	0.015	1.02	1.01–1.03	ABA duration	105	25 (16–42.5)	33 (22–55)	0.087	–	–
Administr.							Administr.						
SC	68	59 (86.8)	9 (13.2)	0.609	–	–	SC	60	41 (68.3)	19 (31.7)	0.378	–	–
IV	52	43 (82.7)	9 (17.3)				IV	45	35 (77.8)	10 (22.2)			
Concomitant csDMARDs							Concomitant csDMARDs						
MTX	42	36 (85.7)	6 (14.3)	0.308	–	–	MTX	37	25 (67.6)	12 (32.4)	0.628	–	–

LFN	14	10 (71.4)	4 (28.6)				LFN	13	9 (69.2)	4 (30.8)			
none	64	56 (87.5)	8 (12.5)				none	55	42 (76.4)	13 (23.6)			
Concom. GCs							Concom. GCs						
Yes	102	91 (89.2)	11 (10.8)	0.002	5.16	1.4–18.58	Yes	89	66 (74.2)	23 (25.8)	0.337	–	–
No	18	11 (61.1)	7 (38.9)				No	16	10 (62.5)	6 (37.5)			
Monotherapy							Monotherapy						
No	113	99 (87.6)	14 (12.4)	0.001	9.13	1.39–68.97	No	98	71 (72.4)	27 (27.6)	0.954	–	–
Yes	7	3 (42.9)	4 (57.1)				Yes	7	5 (71.4)	2 (28.6)			
Number of previous BTs	120	2 (1–3)	2 (1–3)	0.212	–	–	Number of previous BTs	105	2 (1–3)	1 (0–2)	0.038	0.64	0.42–0.94
Duration of previous BTs	120	48 (24–72)	24 (11–63)	0.041	0.98	0.96–0.99	Duration of previous BTs	105	48 (24–84)	24 (0–36)	0.002	0.98	0.97–0.99
Previous BTs							Previous BTs						
Naive	15	12 (80)	3 (20)	0.672	–	–	Naive	14	5 (35.7)	9 (64.3)	0.012	6.60	1.67–29.62
1 TNFi	31	25 (80.6)	6 (19.4)				1 TNFi	28	22 (78.6)	6 (21.4)			
2 TNFis	34	29 (85.3)	5 (14.7)				2 TNFis	31	24 (77.4)	7 (22.6)			
3 or more TNFis	40	36 (90)	4 (10)				3 or more TNFis	32	25 (78.1)	7 (21.9)			
RF							RF						
Negative	24	20 (83.3)	4 (16.7)	0.798	–	–	Negative	22	15 (68.2)	7 (31.8)	0.603	–	–
Positive	96	82 (85.4)	14 (14.6)				Positive	83	61 (73.5)	22 (26.5)			
ACPA							ACPA						

Negative	35	31 (88.6)	4 (11.4)	0.583	–	–	Negative	30	22 (73.3)	8 (26.7)	0.892	–	–
Positive	85	71 (83.5)	14 (16.5)				Positive	75	54 (72)	21 (28)			
DAS28	120	4.92 ± 1.42	3.43 ± 1.33	<0.001	0.44	0.27–0.66	DAS28	105	4.79 ± 1.23	4.20 ± 1.71	0.097	–	–
Baseline NPJ	120	6.5 (3–10)	6 (0.75–8)	<0.001	0.79	0.66–0.91	Baseline NPJ	105	7 (3–10)	5 (2–8)	0.027	0.91	0.82–1.00
Baseline NSJ	120	3 (0–6)	2 (0–3.25)	<0.001	0.68	0.49–0.86	Baseline NSJ	105	3 (1–6)	1 (0–4)	0.112	–	–
PVAS	120	70 (50–80)	50 (30–60)	<0.001	0.95	0.92–0.97	PVAS	105	70 (57.5–80)	50 (30–70)	<0.001	0.97	0.95–0.99
Baseline CRP	120	2 (1–4)	2.65 (1.45–4.38)	0.738	–	–	Baseline CRP	105	2 (1–4)	2 (1.1–4.4)	0.946	–	–
Baseline ESR	120	24 (10–41.25)	20 (8–32.25)	<0.001	0.94	0.89–0.98	Baseline ESR	105	21.5 (10–44.25)	22 (11–32)	0.561	–	–
HAQ	120	1.75 (1.18–2)	1.25 (0.79–2)	0.001	0.32	0.14–0.67	HAQ	105	1.75 (1.20–2.00)	1.20 (0.75–1.60)	0.006	0.43	0.22–0.80
FCGR2A rs1801274							FCGR2A rs1801274						
AA	38	33 (86.8)	5 (13.2)	0.226	–	–	AA	35	25 (71.4)	10 (28.6)	0.981	–	–
GG	29	27 (93.1)	2 (6.9)				GG	25	18 (72)	7 (28)			
AG	53	42 (79.2)	11 (20.8)				AG	45	33 (73.3)	12 (26.7)			
A	91	75 (82.4)	16 (17.6)	0.161	–	–	A	80	58 (72.5)	22 (27.5)	0.961	–	–
G	82	69 (84.1)	13 (15.9)	0.789	–	–	G	70	51 (72.9)	19 (27.1)	0.877	–	–
FCGR3A rs396991							FCGR3A rs396991						
CC	22	19 (86.4)	3 (13.6)	0.313	–	–	CC	21	18 (85.7)	3 (14.3)	0.311	–	–
AA	29	27 (93.1)	2 (6.9)				AA	23	16 (69.6)	7 (30.4)			
CA	69	56 (81.2)	13 (18.8)				CA	61	42 (68.9)	19 (31.1)			
C	91	75 (82.4)	16 (17.6)	0.161	–	–	C	82	60 (73.2)	22 (26.8)	0.794	–	–
A	98	83 (84.7)	15 (15.3)	0.843	–	–	A	84	58 (69)	26 (31)	0.175	–	–

Low-affinity allele <i>FCGR2A/FCGR3A</i>	120	2 (1–3)	2 (1.25–2)	0.438	–	–	Low-affinity allele <i>FCGR2A/FCGR3A</i>	105	2 (1–2)	2 (1–3)	0.406	–	–
---	-----	---------	------------	-------	---	---	---	-----	---------	---------	-------	---	---

ABA: abatacept; ACPA: anti-citrullinated protein antibody; AR: adverse reaction; BT: biological therapy; CI: confidence interval; CRP: C-reactive protein; csDMARD: conventional synthetic disease-modifying antirheumatic drug; DAS28: disease activity score in 28 joints; Dx: diagnosis; ESR: erythrocyte sedimentation rate; EULAR: European League Against Rheumatism criteria; GC: glucocorticoid; HAQ: Health Assessment Questionnaire; IV: intravenous; LFN: leflunomide; MTX: methotrexate; NPJ: number of painful joints; NSJ: number of swollen joints; OR: odds ratio; PVAS: patient visual analogue scale; RA: rheumatoid arthritis; RF: rheumatoid factor; SC: subcutaneous; SD: standard deviation; TNFi: tumor necrosis factor inhibitor.